Aandelen in “Biotechnologie”

Aandeel Datum Koers Evolutie
Geen effecten gevonden.

Nieuws over “Biotechnologie”

04:19 · Ultragenyx Pharmaceutical Inc. Notice of April 6, 2026 Application Deadline for Class Action Lawsuit - Contact Lewis Kahn, Esq. at Kahn Swick & Foti, LLC, Before Application Deadline · Persbericht

04:19 · Ultragenyx Pharmaceutical Inc. Notice of April 6, 2026 Application Deadline for Class Action Lawsuit - Contact Lewis Kahn, Esq. at Kahn Swick & Foti, LLC, Before Application Deadline · Persbericht

04:11 · uniQure N.V. Securities Fraud Class Action Result of FDA Approval Delay and 49% Stock Decline - Investors may Contact Lewis Kahn, Esq, at Kahn Swick & Foti, LLC · Persbericht

13/02 · Nektar Therapeutics Announces Closing of $460 Million Public Offering Including Full Exercise of Underwriters' Option to Purchase Additional Shares · Persbericht

13/02 · AMGEN TO PRESENT AT CITI'S 2026 VIRTUAL ONCOLOGY LEADERSHIP SUMMIT · Persbericht

13/02 · Valneva Provides Update on Recommendations for Use of IXCHIQ® in the United Kingdom · Persbericht

13/02 · Insmed To Present at March 2026 Investor Conferences · Persbericht

12/02 · PTC Therapeutics Provides Regulatory Update on Translarna™ · Persbericht

12/02 · BioMarin Announces Closing of Private Offering of Senior Notes · Persbericht

12/02 · 10x Genomics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Outlook for 2026 · Persbericht

12/02 · GENFIT to receive US$20M milestone after Ipsen’s Iqirvo® exceeds the US$200M threshold in its first full year of net sales   · Persbericht

12/02 · Karyopharm Reports Fourth Quarter and Full Year 2025 Financial Results and Highlights Recent Company Progress · Persbericht

12/02 · Soligenix Details Recent Progress and Upcoming Milestones · Persbericht

12/02 · Compugen Announces the Appointment of Michele Holcomb, Ph.D., to its Board of Directors · Persbericht

12/02 · Tilray Expands UK Pharmaceutical Access Through Strategic Agreement with Smartway Pharmaceuticals · Persbericht

12/02 · Nektar Therapeutics Announces Pricing of Upsized $400 Million Public Offering · Persbericht

11/02 · Biogen Announces Board Chair Transition · Persbericht

11/02 · Viking Therapeutics Reports Fourth Quarter and Year-End 2025 Financial Results and Provides Corporate Update · Persbericht

11/02 · Neurocrine Biosciences Reports Fourth-Quarter and Full-Year 2025 Financial Results and Provides Financial Expectations for 2026 · Persbericht

11/02 · Vanda Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results · Persbericht

11/02 · VALNEVA Declaration of shares and voting rights: January 31, 2026 · Persbericht

Mijn selecties